Joshua A. Ballard - Concepedia

Concepedia

Author

Joshua A. Ballard

Array BioPharma (United States)

Also Known As

J Ballard, J. Ballard, Joshua A Ballard, Joshua A. Ballard, Joshua Ballard

24

Publications

2.1K

Citations

9

H-Index

34

Concepts

All Affiliations

Array BioPharma (United States)Loxo Oncology at Lilly (United States)Mirati Therapeutics (United States)Dana-Farber Cancer Institute

JA

About

Joshua A. Ballard is an author at Array BioPharma (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	334
2	Natural Sciences	2	2	177
3	Biochemistry	2	2	177
4	Chemical Biology	1	1	11
5	Immunology	1	1	139

Joshua A. Ballard

×

9

Publications

2.1K

Citations

9

H-Index

	Year	Citations
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Jill Hallin, Lars D. Engstrom, Lauren Hargis, Cancer Discovery	2019	1.2K
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies Benjamin Solomon, Lavinia Tan, Stephen Q. Wong, Journal of Thoracic Oncology	2020	272
An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt Kui Lin, Jie Lin, Wen‐I Wu, Science Signaling Molecular BiologyConformational ChangesSubstantial Conformational ChangeBioenergeticsReceptor Tyrosine Kinase	2012	166
Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease Yutong Jiang, Steven W. Andrews, Kevin R. Condroski, Journal of Medicinal Chemistry Hepatitis C VirusImmunologyAntiviral DrugViral Structural ProteinHcv Ns3 Protease	2013	139
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity Jay B. Fell, John P. Fischer, Brian R. Baer, ACS Medicinal Chemistry Letters	2018	104
Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor Eliana B Gómez, Kevin Ebata, Hetal S Randeria, Blood	2023	84
Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior Ravi Rajagopalan, Shawn Misialek, Sarah Stevens, Biochemistry	2009	59
Abstract 1464: Pre-clinical characterization of potent and selective next-generation RET inhibitors Gabrielle R. Kolakowski, Erin D. Anderson, Joshua A. Ballard, Cancer Research Chemoprevention StrategyAbstract 1464Molecular BiologyPharmacotherapyPre-clinical Pharmacology	2021	18
Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer Matthew A. Marx, Brian R. Baer, Joshua A. Ballard, Molecular Cancer Research Drug TargetCyanomethyl GroupAbstract B30Chemical BiologyPharmaceutical Chemistry	2020	11

Page 1